Literature DB >> 25801756

Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.

Susann Neiser1, Daniel Rentsch, Urs Dippon, Andreas Kappler, Peter G Weidler, Jörg Göttlicher, Ralph Steininger, Maria Wilhelm, Michaela Braitsch, Felix Funk, Erik Philipp, Susanna Burckhardt.   

Abstract

The advantage of the new generation IV iron preparations ferric carboxymaltose (FCM), ferumoxytol (FMX), and iron isomaltoside 1000 (IIM) is that they can be administered in relatively high doses in a short period of time. We investigated the physico-chemical properties of these preparations and compared them with those of the older preparations iron sucrose (IS), sodium ferric gluconate (SFG), and low molecular weight iron dextran (LMWID). Mössbauer spectroscopy, X-ray diffraction, and Fe K-edge X-ray absorption near edge structure spectroscopy indicated akaganeite structures (β-FeOOH) for the cores of FCM, IIM and IS, and a maghemite (γ-Fe2O3) structure for that of FMX. Nuclear magnetic resonance studies confirmed the structure of the carbohydrate of FMX as a reduced, carboxymethylated, low molecular weight dextran, and that of IIM as a reduced Dextran 1000. Polarography yielded significantly different fingerprints of the investigated compounds. Reductive degradation kinetics of FMX was faster than that of FCM and IIM, which is in contrast to the high stability of FMX towards acid degradation. The labile iron content, i.e. the amount of iron that is only weakly bound in the polynuclear iron core, was assessed by a qualitative test that confirmed decreasing labile iron contents in the order SFG ≈ IS > LMWID ≥ FMX ≈ IIM ≈ FCM. The presented data are a step forward in the characterization of these non-biological complex drugs, which is a prerequisite to understand their cellular uptake mechanisms and the relationship between the structure and physiological safety as well as efficacy of these complexes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25801756     DOI: 10.1007/s10534-015-9845-9

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  30 in total

1.  Enhanced Efficiency of 13C Dynamic Nuclear Polarization by Superparamagnetic Iron Oxide Nanoparticle Doping.

Authors:  Peter Niedbalski; Christopher R Parish; Qing Wang; Zahra Hayati; Likai Song; Zackary I Cleveland; Lloyd Lumata
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2017-08-17       Impact factor: 4.126

2.  Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer® ) versus ferric carboxy-maltose (Ferinject® ). A single center, cohort study.

Authors:  Midas B Mulder; Hester L van den Hoek; Erwin Birnie; Antonie J P van Tilburg; Elsbeth M Westerman
Journal:  Br J Clin Pharmacol       Date:  2018-12-11       Impact factor: 4.335

3.  Iron Sucrose: A Double-Edged Sword in High Phosphate Media-Induced Vascular Calcification.

Authors:  Ping Wang; Chengkun Guo; Hui Pan; Wangshan Chen; Dan Peng
Journal:  Calcif Tissue Int       Date:  2021-01-13       Impact factor: 4.333

Review 4.  Safety and technique of ferumoxytol administration for MRI.

Authors:  Shreyas S Vasanawala; Kim-Lien Nguyen; Michael D Hope; Mellena D Bridges; Thomas A Hope; Scott B Reeder; Mustafa R Bashir
Journal:  Magn Reson Med       Date:  2016-02-18       Impact factor: 4.668

5.  Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents.

Authors:  He Wei; Agata Wiśniowska; Jingxuan Fan; Peter Harvey; Yuanyuan Li; Victoria Wu; Eric C Hansen; Juanye Zhang; Michael G Kaul; Abigail M Frey; Gerhard Adam; Anatoly I Frenkel; Moungi G Bawendi; Alan Jasanoff
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-19       Impact factor: 11.205

6.  Physicochemical characterization of ferumoxytol, heparin and protamine nanocomplexes for improved magnetic labeling of stem cells.

Authors:  L Henry Bryant; Saejeong J Kim; Matthew Hobson; Blerta Milo; Zsofia I Kovacs; Neekita Jikaria; Bobbi K Lewis; Maria A Aronova; Alioscka A Sousa; Guofeng Zhang; Richard D Leapman; Joseph A Frank
Journal:  Nanomedicine       Date:  2016-08-09       Impact factor: 5.307

7.  Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults.

Authors:  Anne M Muehe; Dan Feng; Rie von Eyben; Sandra Luna-Fineman; Michael P Link; Travis Muthig; Amy E Huddleston; Edward A Neuwelt; Heike E Daldrup-Link
Journal:  Invest Radiol       Date:  2016-04       Impact factor: 6.016

Review 8.  Modern iron replacement therapy: clinical and pathophysiological insights.

Authors:  Domenico Girelli; Sara Ugolini; Fabiana Busti; Giacomo Marchi; Annalisa Castagna
Journal:  Int J Hematol       Date:  2017-12-01       Impact factor: 2.490

Review 9.  Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.

Authors:  Peng Zou; Katherine Tyner; Andre Raw; Sau Lee
Journal:  AAPS J       Date:  2017-07-31       Impact factor: 4.009

10.  In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations.

Authors:  Amy Barton Pai; Manjunath P Pai; Dan E Meyer; Brian C Bales; Victoria E Cotero; Nan Zheng; Wenlei Jiang
Journal:  Regul Toxicol Pharmacol       Date:  2018-05-29       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.